RP — Replicel Life Sciences Income Statement
0.000.00%
Last trade - 00:00- CA$3.38m
- CA$3.39m
- CA$0.35m
Annual income statement for Replicel Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.121 | 0.354 | 0.354 | 0.354 | 0.354 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.86 | 3.17 | 1.68 | 2.62 | 1.75 |
| Operating Profit | -2.74 | -2.82 | -1.33 | -2.27 | -1.39 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.77 | -3 | -1.58 | -4.07 | -0.743 |
| Net Income After Taxes | -2.77 | -3 | -1.58 | -4.07 | -0.743 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.77 | -3 | -1.58 | -4.07 | -0.743 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.77 | -3 | -1.58 | -4.07 | -0.743 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.122 | -0.129 | -0.059 | -0.126 | -0.02 |